Free tool
FAERS Monitor: Mydayis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022063 or its brand name (Mydayis, Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate). Reports on generic versions are filed under their own applications.
Reports
879
Serious
184
21% of reports
Hospitalization
36
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective219
- fatigue61
- insomnia57
- headache53
- anxiety49
- off label use49
- feeling abnormal47
- product availability issue47
- no adverse event46
- inability to afford medication43
- somnolence41
- insurance issue39
- nausea35
- disturbance in attention31
- depression30
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 83 |
| 2018 | 239 |
| 2019 | 97 |
| 2020 | 79 |
| 2021 | 95 |
| 2022 | 62 |
| 2023 | 81 |
| 2024 | 72 |
| 2025 | 40 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,280 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inability to afford medicationSignal | 43 | 104.1 | 77.7 | 4,270 |
| insurance issueSignal | 39 | 61.2 | 45.0 | 2,245 |
| product availability issueSignal | 47 | 49.5 | 37.5 | 2,183 |
| disturbance in attentionSignal | 31 | 13.8 | 9.7 | 355 |
| no adverse eventSignal | 46 | 6.1 | 4.6 | 192 |
| insomniaSignal | 57 | 5.1 | 4.0 | 187 |
| somnolenceSignal | 41 | 4.9 | 3.6 | 124 |
| feeling abnormalSignal | 47 | 4.7 | 3.6 | 134 |
| anxietySignal | 49 | 4.1 | 3.1 | 114 |
| drug ineffectiveSignal | 219 | 4.0 | 3.5 | 517 |
| depressionSignal | 30 | 3.2 | 2.2 | 42 |
| headacheSignal | 53 | 2.0 | 1.6 | 27 |
| fatigue | 61 | 1.9 | 1.5 | 25 |
| off label use | 49 | 1.3 | 1.0 | 4 |
| nausea | 35 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.